Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.
INTRODUCTION
Synovial sarcoma is a soft-tissue malignancy with a predilection for adolescents and young adults. 1 Approximately half of patients diagnosed with synovial sarcoma will die from disease, that portion much higher in those who present with or develop metastasis. Targeted therapeutic strategies are both lacking and greatly needed.
Synovial sarcomas bear a characteristic chromosomal translocation between chromosomes 18 and X, generating a fusion oncogene comprised of the promoter and 5 0 -coding sequence of SS18 (previously called SYT) through its tenth exon and the 3 0 coding sequence of an SSX gene, SSX1, SSX2, or SSX4. 1 Expression of the human SS18-SSX2 complementary DNA (cDNA) in certain tissues induces synovial sarcomagenesis in mice. 2, 3 The fusion oncoprotein functions as a bridge between ATF2, bound to CREs in the promoters of target genes, and TLE1, which recruits histone deacetylase and the polycomb group repressor complex, resulting in epigenetic gene silencing. 4 A high level of BCL2 is considered part of the definitional synovial sarcoma expression signature. 5 Nearly all synovial sarcomas will stain for high levels of BCL2 by immunohistochemistry. 6, 7 Although apoptosis pathways have not been thoroughly investigated to define a tumor-specific role for BCL2 in synovial sarcoma, BCL2 is suspected to contribute to resistance to cytotoxic chemotherapies. 8 Antisense knock-down of BCL2
was previously noted to sensitize synovial sarcoma cells to doxorubicin-induced apoptosis. 9 A new class of compounds antagonizes BCL2 family members more generally by mimicking the BH3 domain, through which BCL2, BCL-xL, and BCL-w act to suppress downstream activators of apoptosis. 10 ABT-263, an orally available BH3-domain peptidomimetic was found to be safe and marginally effective against follicular cell lymphoma and small cell lung cancer in phase I trials. 11, 12 A primary challenge to its efficacy has been the tendency of cancers to upregulate alternate anti-apoptotic genes, unaffected by ABT-263. Specifically, MCL1 is the most common route of escape from ABT-263, with BCL2A1 as another means of evasion. 13, 14 We show that the biology inherent to synovial sarcomagenesis suppresses these escape routes, enabling tumor sensitivity to this new class of pharmaceuticals.
RESULTS AND DISCUSSION
In order to investigate apoptotic pathway members in synovial sarcomas, we assembled a list of genes directly involved in apoptosis by combining related Kegg pathway and Gene Ontology gene lists and then dividing them into anti-and proapoptotic components (Supplemental Table 1 ). We interrogated published and publicly available mouse synovial sarcoma expression profiles from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo, profiles GSE6461 and GSE14469, 2, 3 ) using D-chip software (www.dichip.org) 15 with an alpha of 0.05 as the criterion for stringency (Figure 1a and Supplemental Figure 1a ). While Bcl2 expression was elevated in tumors, more striking was the unusual balance of apoptotic pathways, with upregulation of many pro-apoptotic members and the consistent downregulation of Mcl1 (Figure 1a and Supplemental Figure 1a) . Similar patterns were confirmed by comparing 29 human synovial sarcomas from GSE20196 16 to five human mesenchymal stem cell control samples from GSE26272 17 (Supplemental Figures 1b and c ). An additional analysis compared 16 human synovial sarcomas with 21 human malignant fibrous histiocytomas (soft-tissue sarcomas without SS18-SSX expression) from the prior study set GDS2763. 18 In this tumor-to-tumor comparison, BCL2 had 2.7-fold higher expression (t-test P ¼ 0.0002) and MCL1 1.7-fold lower expression (P ¼ 0.002) in the synovial sarcomas.
The strong consistency of high BCL2 levels in synovial sarcomas prompted the hypothesis that BCL2 expression is regulated by the SS18-SSX fusion oncogene. The promoter of the BCL2 gene in both the human and mouse genomes bears a CRE with a conserved and typical ATF-binding sequence. Some genes with promoters bearing CREs have been shown to be directly suppressed by SS18-SSX binding to the promoter via ATF2 and recruiting TLE1. order to investigate the control exerted by SS18-SSX2 on expression of BCL2, we performed both overexpression of SS18-SSX2 in naive cells and knock-down of the fusion oncogene in synovial sarcoma cells. Mouse embryonic fibroblasts (MEFs) heterozygous for conditionally activatable SS18-SSX2 in the Rosa26 locus were harvested from day 14.5 embryos, dissociated in trypsin and plated in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum. Cre-mediated recombination to activate SS18-SSX2 expression in these MEFs was achieved by the application of 5 mM TATCre protein in DMEM. 19 When induced to express SS18-SSX2, the MEFs showed increased levels of Bcl2 by quantitative polymerase chain reaction (qPCR) following reverse transcriptase (RT) PCR from total RNA harvested at 48 h (Figure 1b ). For the opposite experiment, thoracic cage tumors from our previously reported mouse model of synovial sarcoma were harvested from 15-week-old mice, dissociated in collagenase, hyaluronidase and DNase, then plated in DMEM with 10% fetal bovine serum. Short interfering RNA (siRNA) was applied using the Lipofectamine RNAiMax reagent (Sigma, St Louis, MO, USA) as previously described. 4, 20 Bcl2 levels decreased in response to siRNA against SS18-SSX2 transcripts versus scrambled siRNA controls in cells derived from mouse synovial sarcomas (Figures 1c and d ). This suggests that the fusion oncoprotein promotes Bcl2 expression. For a human correlate, we used the SYO1 cell line, derived from a human synovial sarcoma expressing SS18-SSX2, kindly provided by Akira Kawai (National Cancer Center Hospital, Tokyo). 21 Similar decrease in BCL2 expression was noted in the SYO1 cells upon siRNA directed against SS18-SSX2 (Figures 2a and b ). To determine whether or not SS18-SSX2 and its repressor complex could be identified at the putative ATF2 binding site in the BCL2 promoter CRE, we performed chromatin immunoprecipitation (ChIP) in SYO1 cells using antibodies directed against each known member of the complex, SS18-SSX2, ATF2 and TLE1 (Figure 2c ). This ChIP identified none of these components bound to the BCL2 CRE (Figures 2c and d) . From these data we conclude that BCL2 transcriptional regulation by SS18-SSX2 either uses a distinct mechanism or is indirectly impacted by SS18-SSX2 suppressing another BCL2 suppressor.
Given the consistent downreglation of Mcl1/MCL1 in synovial sarcoma expression profiles (Figure 1a, Supplemental Figure 1b) , we investigated the effects of SS18-SSX2 on this and other members of the mitochondrial apoptosis pathway. Specifically, levels of Bcl2a1a decreased in MEFs following induction of the expression of SS18-SSX2 (Figure 1b) . Mcl1 levels also trended toward downregulation in that setting, but not significantly (Figure 1b and Supplemental Figure 2 ). In mouse synovial sarcoma cells, both Mcl1 and Bcl2a1a levels increased markedly upon knock-down of SS18-SSX2 using siRNA (Figures 1c and d) . Similarly, knock-down of SS18-SSX2 in the human SYO1 cell line produced increased levels of both MCL1 and BCL2A1 (Figure 2a ). These data suggest that the expression of both MCL1 and BCL2A1 may be suppressed by the expression of SS18-SSX2 in the tumors. However, the fact that the impact of SS18-SSX2 on the expression of Mcl1 in the MEFs was not similarly significant suggests that the transcriptional regulation by SS18-SSX2 of Mcl1 must be contextdependent. In similar fashion, a change in SS18-SSX2 expression demonstrated the opposite effect on Bcl-xL in the tumor and MEF settings, also displaying context-dependence. Context-dependent transcriptional regulation fits well into the paradigm of the known epigenetic mechanism of recruiting polycomb group proteins and histone deacetylases (HDACs) to the CREs of target genes.
Both MCL1 and BCL2A1 have conserved CREs with putative ATFbinding sites (Figure 2c) . In order to ascertain if these genes are directly suppressed by SS18-SSX2, we performed ChIP in the SYO1 cells. Indeed, each known member of the suppressive complex was identified as bound to the CRE in the promoters of both genes (Figure 2c) . Further, siRNA directed against ATF2, the DNA-binding member of the complex, released the complex from the CRE in each promoter (Figure 2c ). These data confirm MCL1 and BCL2A1 as novel direct targets of SS18-SSX-driven repression in the synovial sarcoma context using ATF2 promoter binding.
Observing that BCL2 and MCL1 specifically have opposite responses to a change in the expression level of SS18-SSX2 in synovial sarcoma cells, we asked whether either MCL1 or BCL2 might have a role in indirectly regulating the expression of the other, as a negative feedback loop for the mitochondrial antiapoptotic pathway. In knock-down of either gene, response of the other was modest at best in SYO1 cells (Figure 2d) . The observed modest decrease in BCL2 expression following siRNA directed against MCL1 may have derived from inadvertent suppression of SS18-SSX2 itself. No change in the non-targeted gene expression was noted in another human cancer cell line, suggesting that these anti-apoptotic genes may have some subtle relationship in the synovial sarcoma cells specifically. We also observed that knock-down of either gene, or the combination did not discernibly change the growth and proliferation of the SYO1 cells. This fits with prior observations that Genasense, an antisense oligonucleotide pharmaceutical directed against BCL2, enhanced sensitivity to doxorubicin, but was not cytotoxic or growth suppressive as a single agent. 9 There are likely other anti-apoptotic genes that fillin for BCL2's downregulation, but MCL1 itself is an unlikely candidate in these tumors.
Cancers that have evaded BH3-domain peptidomimetic pharmacotherapy have primarily utilized either MCL1 or BCL2A1 as means of avoiding apoptosis in the setting of drug-antagonized BCL2, BCL-xL, and BCL-w. 13, 14 New appreciation that both MCL1 and BCL2A1 are direct targets of SS18-SSX-driven suppression suggests that synovial sarcomas might be susceptible to BH3-domain peptidomimetic pharmacotherapy. In order to test this hypothesis, cells derived from our mouse model of synovial sarcoma were plated in 96-well plates. One, two or three days following the addition of varied concentrations of ABT-263 or dimethyl sulfoxide vehicle, cells were washed and incubated with 5 mg/ml thiazolyl blue tetrazolium bromide (MTT, Sigma). Mouse synovial sarcoma cells were modestly sensitive to the BH3-domain peptidomimetic, but only after 2 days (Figure 3a) . As the most clinically desirable effect of pharmacologic blockade of the antiapoptotic members of the mitochondrial pathway would be to enhance sensitivity to traditional cytotoxic chemotherapy, the concentrations of ABT-263 and doxorubicin were varied independently in a similar proliferation assay. ABT-263 enhanced the growth-suppression of doxorubicin at nanomolar concentrations (Figure 3a) .
To confirm that these quantitative assays were highlighting true changes in cytotoxicity, rather than metabolic rate alone, cell counts of apparently adherent, viable cells were performed one day following treatments, immediately before application of the MTT assay reagents. Indeed, cell counts corroborated the suspicion that the quantitative proliferation assay changes derived from cell growth and survival, not simply changes in metabolism (Supplemental Figure 3) .
To rule out the possibility that the observed sensitivity to ABT-263 derived from non-specific toxicity alone, MTT assays were performed simultaneously comparing the human SYO1 synovial sarcoma cell line to five other human cancer cell lines, all treated with identical dosing combinations (Figure 3b) . Response of any kind was discernible in only one other cell line, and that only a partial response and only in combination with doxorubicin. From this we concluded that the synovial sarcoma responsiveness to ABT-263 cannot be attributed to non-specific toxicity alone, but rather some targeted effect. With regard to the interaction between ABT-263 and doxorubicin, it fell on the synergistic side of the isobologram generated for each (Figure 3c) .
We next evaluated the expression of mitochondrial antiapoptotic genes following administration of ABT-263 or doxorubicin. The greater sensitivity of SYO1 cells to ABT-263 required that a very low dose of ABT-263 be applied, in order to have cells remaining after treatment from which RNA might be isolated. In cells that evaded the cytotoxicity for a full day, expression of BCL2, MCL1 and BCL2A1 was elevated (Figure 3d ). True to the epigenetic mechanism of SS18-SSX2-mediated gene suppression, neither MCL1 nor BCL2A1 completely loses the capacity to respond to other factors that control expression. However, each is suppressed sufficiently to render the response in most cells insufficient to support full evasion of apoptosis. The levels of BCL2A1 are so low in SYO1 cells, that even after tripling in expression, it remains three orders of magnitude lower in its expression than BCL2 itself.
The natural history of mice expressing the human cDNA SS18-SSX2 in cells that express Myf5-Cre includes consistent tumor formation by the age of 12 weeks. The most frequent site of disease is the intercostal muscles of the thoracic cage, where 3-8 tumors are typically detectable by that age. These then grow over the ensuing weeks. With approval of the university institutional animal care and use committee, mice were treated beginning in the thirteenth week with three-times weekly doses of either 2.5 ml/ gram body mass dimethyl sulfoxide vehicle or the same with ABT-263 dissolved at the concentration of 20 mg/ml (for 50 mg/kg dosing regimen) or 30 mg/ml (for 75 mg/kg dosing). Mice were euthanized at 15 weeks of age. The thoracic cage of each mouse was dissected of all muscles but the intercostals. Tumors identified grossly and confirmed by green fluorescent protein fluorescence were counted, excised, and weighed (Figure 4a ). Histology then confirmed that each mass measured matched the typical Figure 2 . SS18-SSX2 in a human synovial sarcoma cell line also directly suppresses expression of MCL1 and BCL2A1 and can be identified at their promoters. (a) SYBR green qPCR of cDNAs made from total RNA isolated from the SYO1 human synovial sarcoma cell line 48 h following siRNA directed against SS18-SSX2 or scrambled control confirms downregulation of BCL2 and BCL-xL and upregulation of MCL1, BCL2A1 and BCL-w (ATF3 is a 'positive' control, known to be directly suppressed by SS18-SSX2 in this cell line). (b) Western confirms the same directional changes at the protein level, from extracts obtained 72 h post application of the siRNA. (c) The ATF binding sequence in the CRE in the promoters of each of the genes in question shows perfect cross-species homology between mouse and human. However, ChIP with an antibody directed against the SS18-SSX junction identifies that CRE bound at the MCL1 and BCL2 A1 promoters, but not at BCL2. Further, ChIP with an antibody directed against each of the members of the expression-suppressing complex identifies each at the same promoters, but released from the promoter 72 h following siRNA directed against ATF2, the DNA-binding member of the complex. Each experiment was performed with a sample of at least three and independently repeated. (d) By 48 h following application of siRNA directed against scrambled control, BCL2, MCL1 or both BCL2 and MCL1, expression levels of targets were confirmed to be knocked down in both SYO1 cells and the DLD.1 human colon cancer cell line. No off target effects were noted in DLD.1 cells, but BCL2 was noted to be downregulated upon application of siRNA against MCL1 in SYO1 cells. (All results are presented as mean þ / À s.d. All comparisons with P-valueso0.05 by Student's t-test are indicated with an asterisk.).
appearance of a synovial sarcoma in this model (Figure 4b ). Experimental and control mice from the same litters were used for the studies. As a single agent in this setting, ABT-263 reduced the number of tumors at the higher dose, and the total mass of tumors per mouse thoracic cage at both doses compared with control vehicle (Figure 4) . ABT-263 is often dosed orally in other mouse models, but could not be in these mice due to typically severe kyphosis (a non-tumor phenotype of their genetic manipulation) affecting esophageal access. Even accounting for enhanced bioavailability via the intraperitoneal administration, the doses we used are much lower than the typical 75 mg/kg body mass daily for 3 weeks. Further, we did not observe any toxicity in other tissues from the doses used. One mouse in the higher-dose group became moribund before the last treatment, but this cannot strictly be attributed to any drug toxicity, as this naturally occurs at a relatively high background rate in these mice. Given the modest sensitivity of the cells derived from similar mouse synovial sarcomas to ABT-263 as a single agent, this marked in vivo responsiveness suggests that the drug may inhibit evasion of cellto-cell or immune-mediated induction of apoptosis, rather than cell intrinsic alone.
These data provide a molecular rationale for treatment of synovial sarcomas with this new class of BH3-domain peptidomimetics. Further, they illustrate the capacity of a genetic mouse model of a human cancer, not only as a platform for preclinical evaluation of treatment strategies, but also as tool for deciphering pathways important in mediating their molecular effects. Given the relatively small numbers of human synovial sarcomas treated at any single referral sarcoma unit, there is an urgent need to develop molecularly targeted therapies that have a high chance of efficacy in the clinic before initiating clinical trials. If drugs or regimens and their biology can be credentialed in an in vivo synovial sarcomagenesis model, therapeutic strategies may be prioritized; more effective clinical trials may be performed. 
